Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral ketamine plus intermittent theta burst stimulation for PTSD
ACTRN12621000342819Phase 2Terminated
- Sponsor
- Thompson Institute
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine in post-traumatic stress disorder (PTSD) (2 arms), sponsored by Thompson Institute. Primary endpoint: PTSD symptomology by PCL-5 from baseline to Follow-up 1. Started Jul 2021; status: terminated.
02
Drugs
ketamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on ACTRN12621000342819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000342819.